Laura Franshaw

Laura Franshaw is a female medical professional who specializes in treating brain stem cancer, diffuse midline glioma H3 K27M-mutant, brain tumors, gliomas, gliomatosis cerebri, and posterior fossa tumors.

Laura Franshaw helps patients by using special skills and treatments to address their brain-related conditions. She communicates with patients in a caring and clear way, earning their trust through her expertise and compassion.

To stay updated with the latest medical knowledge and research, Laura Franshaw regularly attends conferences, reads medical journals, and collaborates with other experts in the field. This ensures that she can provide the best possible care to her patients.

Laura Franshaw works closely with colleagues and other medical professionals to ensure a comprehensive approach to patient care. By fostering strong relationships with her peers, she can exchange ideas, seek advice, and collaborate on complex cases.

Through her dedication and expertise, Laura Franshaw has made a positive impact on many patients' lives and health. Her work has led to improved outcomes, better quality of life, and increased hope for those facing challenging brain conditions.

One of Laura Franshaw's notable publications is "High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic," published in Neuro-oncology on May 11, 2024. This research highlights her commitment to advancing treatment options for patients with brain tumors.

In summary, Laura Franshaw is a caring and skilled medical professional who is dedicated to providing the best possible care for patients with brain-related conditions. Through her expertise, communication skills, continuous learning, and collaborative approach, she has positively impacted many lives and contributed to advancements in the field of neuro-oncology.